# A Study in Patients With Chronic Obstructive Pulmonary Disease

> **NCT01245569** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 373 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Foster® 100/6 µg/unit dose
- **DRUG:** Seretide Accuhaler® 500/50 µg/actuation

## Key facts

- **NCT ID:** NCT01245569
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245569, "A Study in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*